Biolex Therapeutics, a US-based company, and Kringle Pharma launched joint research on the development of low-cost mass production methods for NK4, an antitumor protein.

Biolex Therapeutics, a US-based company, and Kringle Pharma launched joint research on the development of low-cost mass production methods for NK4, an antitumor protein.